LINC00482 targets miR-877-3p to modulate osteogenic differentiation in fracture patients.

OBJECTIVE: To investigate the diagnostic value of LINC00482 in patients with fractures and its regulatory role in osteogenic differentiation. METHODS: A total of 194 participants were enrolled, of whom 103 had fractures. Fracture occurrence was determined via X-ray examination, and 5 mL of fasting venous blood was collected from all participants. Logistic regression analysis was employed to predict risk factors influencing fracture development. Receiver operating characteristic (ROC) curves assessed the diagnostic value of LINC00482 and miR-877-3p for fractures. RT-qPCR measured gene expression, while the CCK-8 assay evaluated cell proliferation. Dual luciferase reporter assays validated interactions between the target genes. Pearson correlation analysis examined the relationship between their expression relationship in fracture patients' serum. RESULTS: Serum from fracture patients exhibited significantly elevated LINC00482 levels and markedly reduced levels of miR-877-3p. Both demonstrated diagnostic value in predicting fracture occurrence. LINC00482, osteocalcin (OCN), and osteopontin (OPN) were identified as risk factors for fracture development. Transfection with si-LINC00482 promoted osteoblast proliferation and differentiation, and miR-877-3p was identified as a downstream target gene of LINC00482. The miR inhibitor reduced alkaline phosphatase (ALP) activity and inhibited osteoblast proliferation and differentiation. CONCLUSION: LINC00482 may inhibit osteoblast proliferation and osteogenic differentiation by targeting miR-877-3p, thereby impeding fracture healing.